Since February 2012
A network approach to immune modulation - A new approach to network regulation and dynamic of disease based on peptide sequence motifs shared by the different disease-associated proteins (DAP).
Since January 2011
Science in action Ltd. is a CRO company conveniently located in the Weizmann Science Park in Israel specializing in preclinical contract research and services. SIA is renowned for accompanying biotechnology and drug discovery startups from inception, proposing unconventional solutions and guiding company management through early stages of pre-clinical work up until demonstration of proof of concept.
Since January 2006
Founder of SymThera, a Member of the Board of Directors, and has served as Chief Science Officer since January 2006. Chai is a graduate of Ben Gurion University, Israel (Chemistry), Montreal University, Canada (Biochemistry) and The Weizmann Institute of Science, Israel (Life Sciences). Chai pioneered the concept of balance in the chemokine network and developed a biological infrastructure that has validated the concept in animal models of disease.
Since May 2005
COMPANY HIGHLIGHTS - Drug Discovery and Development for the treatment of Autoimmune Diseases: Multiple Sclerosis, Crohn's Disease, Arthritis, Psoriasis http://www.implu.com/patent_applicant/1237390 - Biological Drugs Modulators of the dysfunctional immune system; High Specificity, Low Toxicity Drugs - Bioinformatics Program Proprietary drug discovery algorithm for the rational discovery and design of novel therapeutics - Unique Technological Platform Proprietary technologies for the rapid engineering, production and screening of drug candidates - Therapeutic Activity Drug candidates with therapeutic activity in an animal model of disease Chai Ezerzer: Chief Scientific Officer firstname.lastname@example.org
Research Assistant / Ph.D. Student.
January 2000 --- January 2004
Research Topic: Development of cloning technology. Identification and characterization of BKT-RP3; peptide that specifically binds to the chemokines IL-8 and Mig, with pharmaceutical grade affinity.
AdaptabilityAnalytical thinkingApproachabilityAttention to detail
Skills and Expertise
Biomarker Research Interpret data Molecular DiagnosticsClinical data collection
studies toward Ph.D. in Department of Gene therapy from Hebrew University of Jerusalem in 2004
studies toward Ph.D. in Department of Immunology from Weizmann Institute of Science in 2000
M.Sc. in Department of Biological Chemistry from Weizmann Institute of Science in 1999
B.Sc. in Biochemistry. from Université de Montréal / University of Montreal in 1996